Abstract
AbstractBackgroundHypertension is a risk factor for Alzheimer’s disease, however relationships between this disease and CSF amyloidβ42, total tau and phosphorylated tau (p‐181) are inconclusive. Even less is known about associations between trajectories of blood pressure and AD biomarkers.MethodLongitudinal CSF examinations were performed in 132 normotensive subjects (BP<140/90, and no antihypertensive treatment), 35 subject with controlled hypertension ((BP<140/90, and antihypertensive treatment), and 32 subjects with uncontrolled hypertension (BP≥140/90, irrespective of treatment), mean age 64.3 ± 9.3 years, 61% women.Biomarker changes over time, and relationship between changes in biomarkers and changes in systolic and diastolic blood pressure were tested using repeated measures mixed model.ResultNormotensive group was younger than 2 other groups, percentage of women did not differ. Baseline biomarkers levels were not different between groups.After a mean follow‐up time of 3.7±2.7 years total tau and p‐tau181 increased in the normotensive and uncontrolled groups, but did not change in the controlled group (group*time: F=3.2, p=.04 and F=3.2, p=.04 for total tau and p‐tau181, respectively). Amyloidβ42 remained unchanged in the normotensive and controlled groups, but decreased in the uncontrolled group (group*time: F=3.1, p=.04).Change in systolic blood pressure was inversely related to change in total tau only in the uncontrolled group (group*time: F=5.0, p=.007). Change in diastolic blood pressure was inversely related to change in ptau‐181 tau only in the uncontrolled group (group*time: F=4.2, p=.02). No other relationship between blood pressure and biomarkers was detected.ConclusionSubjects with baseline uncontrolled hypertension experienced longitudinal changes in amyloid and tau markers most consistent with progression toward Alzheimer’s disease. Interestingly, in this group increases in tau and p‐tau181 coincided with reduction in blood pressure. This may indicate relationship with relative hypoperfusion in subjects with vasculature compromised by years of high blood pressure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.